Hematology-Oncology, Department of Pediatrics, Weill Cornell Medical College, 515 East 71st Street, New York, NY 10021, USA.
Hematol Oncol Clin North Am. 2010 Dec;24(6):1089-107. doi: 10.1016/j.hoc.2010.08.003. Epub 2010 Oct 15.
β-Thalassemia is a genetic disorder caused by mutations in the β-globin gene and characterized by chronic anemia caused by ineffective erythropoiesis, and accompanied by a variety of serious secondary complications such as extramedullary hematopoiesis, splenomegaly, and iron overload. In the past few years, numerous studies have shown that such secondary disease conditions have a genetic basis caused by the abnormal expression of genes with a role in controlling erythropoiesis and iron metabolism. In this article, the most recent discoveries related to the mechanism(s) responsible for anemia/ineffective erythropoiesis and iron overload are discussed in detail. Particular attention is paid to the pathway(s) controlling the expression of hepcidin, which is the main regulator of iron metabolism, and the Epo/EpoR/Jak2/Stat5 signaling pathway, which regulates erythropoiesis. Better understanding of how these pathways function and are altered in β-thalassemia has revealed several possibilities for development of new therapeutic approaches to treat of the complications of this disease.
β-地中海贫血是一种由β-珠蛋白基因突变引起的遗传性疾病,其特征是无效造血导致的慢性贫血,并伴有多种严重的继发性并发症,如骨髓外造血、脾肿大和铁过载。在过去的几年中,大量研究表明,这些继发性疾病状况具有遗传基础,是由控制红细胞生成和铁代谢的基因异常表达引起的。本文详细讨论了与贫血/无效造血和铁过载相关的最新机制发现。特别关注调控铁代谢主要调节剂铁调素(hepcidin)表达的途径,以及调节红细胞生成的 Epo/EpoR/Jak2/Stat5 信号通路。更好地了解这些途径的功能及其在β-地中海贫血中的改变,揭示了开发治疗这种疾病并发症的新治疗方法的几种可能性。